Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Rhea-AI Summary

Annovis (NYSE: ANVS)/b) priced an underwritten offering of of common stock with accompanying warrants at a combined price of $1.90 per share/warrant, expected to raise approximately $10 million in gross proceeds before fees.

Each warrant is exercisable for one share at $2.50, becomes exercisable six months after issuance, and expires five years and six months after issuance. Closing is expected on or about April 10, 2026. Net proceeds will fund Phase 3 development of buntanetap and general corporate purposes.

Positive

• Gross proceeds of approximately $10 million
• Proceeds earmarked for Phase 3 buntanetap development

Negative

• Potential dilution from 5,263,156 new shares and warrants
• Warrants exercisable at $2.50 could increase future dilution

News Market Reaction – ANVS

-29.57% 11.9x vol

43 alerts

-29.57% Session close to close

-28.5% Trough in 25 hr 20 min

$65.22M Market Cap

11.9x Rel. Volume

In the Apr 9 session, ANVS declined 29.57%, reflecting a significant negative market reaction. Argus tracked a trough of -28.5% from its starting point during tracking. Our momentum scanner triggered 43 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 11.9x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -29.6% in the session following this news. A negative reaction despite the stated ...

Analysis

The stock dropped -29.6% in the session following this news. A negative reaction despite the stated use of proceeds for Phase 3 development would fit the historical pattern of dilution concerns around ANVS offerings. Prior financing headlines produced an average move of -7.83%, with some selloffs exceeding -30%. As new shares and warrants enter the float, pressure from existing holders and trading around the deal terms could further influence sentiment.

Key Figures

Shares offered: 5,263,156 shares Warrants offered: 5,263,156 warrants Combined offering price: $1.90 per share+warrant +5 more

8 metrics

Shares offered 5,263,156 shares Common stock in underwritten offering

Warrants offered 5,263,156 warrants Accompanying common stock warrants

Combined offering price $1.90 per share+warrant Pricing of underwritten offering

Warrant exercise price $2.50 per share Exercise price for each warrant

Expected gross proceeds approximately $10 million Before underwriting fees and expenses

Warrant term 5 years and 6 months Expiration after date of issuance

Expected closing date April 10, 2026 Planned closing of underwritten offering

Phase Phase 3 Clinical stage of buntanetap program

Previous Offering Reports

5 past events · Latest: Oct 27 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Oct 27	Registered direct offering	Negative	+4.9%	Registered direct offering at $2.05 for about $3.4M gross proceeds.
Oct 15	Offering closed	Negative	+12.2%	Closing of $6.0M registered direct offering at $1.50 per share.
Oct 10	Registered direct deal	Negative	-22.7%	Definitive agreements for $6M registered direct at $1.50 per share.
Feb 4	Public offering closed	Negative	+0.0%	Closing of $21M public offering of shares plus five‑year warrants.
Feb 3	Public offering pricing	Negative	-33.5%	Pricing of $21M public offering at $4.00 with $5.00 exercise warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past equity offerings often saw negative average moves, though individual reactions ranged from sharp selloffs to double‑digit gains.

Recent Company History

Over the past year, ANVS has repeatedly used public and registered direct offerings to fund development of buntanetap and general corporate needs. Prior raises in Feb 2025 and Oct 2025 generated gross proceeds between $3.4M and $21M, typically via common stock plus warrants under a Form S‑3 shelf. Price reactions around these financings varied, from declines greater than 30% to double‑digit gains, underscoring inconsistent market responses to dilution-driven capital raises.

Key Terms

underwritten offering, warrants, exercise price, bookrunner, +4 more

8 terms

underwritten offering financial

"today announced the pricing of an underwritten offering of 5,263,156 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

warrants financial

"together with accompanying warrants to purchase up to 5,263,156 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

exercise price financial

"Each warrant will be exercisable for one share of common stock at an exercise price of $2.50"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

bookrunner financial

"Canaccord Genuity is acting as the sole bookrunner for the offering."

A bookrunner is the lead bank or financial firm that organizes and manages a new securities offering, acting like a project manager who sets the price range, collects investor demand, and decides how shares are allocated. For investors, the bookrunner’s choices and reputation influence the final price, how many shares each buyer receives, and the overall chance the deal succeeds — similar to how a trusted referee shapes a fair and well-run auction.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3 (Registration No. 333-276814)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (Registration No. 333-276814)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"The offering is being made only by means of a prospectus supplement that forms a part"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

base prospectus regulatory

"including a base prospectus, previously filed with the Securities and Exchange Commission"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.50 per share of common stock, will be exercisable commencing six months following the issue date and will expire five years and 6 months after the date of issuance.

All of the shares of common stock and the accompanying warrants are being offered by Annovis. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the offering.

Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $10 million, excluding potential proceeds from the exercise of the warrants. The offering is expected to close on or about April 10, 2026, subject to the satisfaction of customary closing conditions.

Canaccord Genuity is acting as the sole bookrunner for the offering.

Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimer’s disease, and for working capital and general corporate purposes. The shares and accompanying warrants are being offered by Annovis pursuant to a shelf registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering is being made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30^th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

What did Annovis (ANVS) announce about the April 2026 offering?

Annovis announced an underwritten offering of 5,263,156 shares with warrants at $1.90 combined. According to the company, the offering is expected to close on or about April 10, 2026 and will generate approximately $10 million in gross proceeds before fees.

How do the warrants in the ANVS offering work and when do they expire?

Each warrant in the offering is exercisable for one share at $2.50 and vests after six months. According to the company, each warrant expires five years and six months after issuance, providing a multi‑year exercise window for holders.

How will Annovis (ANVS) use the net proceeds from the offering?

Annovis intends to use net proceeds to continue Phase 3 development of buntanetap and for working capital. According to the company, funds are targeted to support the lead compound's clinical program and general corporate purposes.

What is the expected dilution impact of Annovis (ANVS) offering on shareholders?

The offering adds 5,263,156 new shares plus warrants convertible into the same number of shares, increasing share count if exercised. According to the company, potential dilution arises from both issued shares and future warrant exercises at $2.50.

Who is managing the Annovis (ANVS) underwritten offering and where is the prospectus filed?

Canaccord Genuity is acting as sole bookrunner for the offering. According to the company, the offering is made under an existing Form S-3 registration (No. 333-276814) and a prospectus supplement will be filed with the SEC.